Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN EBITDA Margin
EBITDA as a percentage of revenue.
Illumina, Inc.NASDAQ: ILMN
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to 28.5%
EBITDA Margin was 28.5% in Q2 FY2026, down 9.3 pp from a year earlier. On a trailing-twelve-month basis it was 30.3%, down 11.3 pp year over year. Over 3 fiscal years it widened by 119.0 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 14 analysts of 27.0% for the fiscal year ending Dec 2026, down from 33.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 28.5%+5.6 pp QoQ
- Last fiscal yearDec 2025
- 33.6%+50.2 pp YoY
- LTMJun 2026
- 30.3%-11.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.3 pp | -3.1 pp | +6.1 pp |
| 1 year | +50.2 pp | -6.6 pp | -56.7 pp |
| 3 years | +119.0 pp | -5.1 pp | -124.1 pp |
| 5 years | -3.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 33.6%
- Year-over-year change
- +50.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 33.6% | +50.2pp |
| FY2024 | 2024-12-29 | -16.6% | -3.1pp |
| FY2023 | 2023-12-31 | -13.5% | +71.9pp |
| FY2022 | 2023-01-01 | -85.4% | -111.9pp |
| FY2021 | 2022-01-02 | 26.4% | — |
EBITDA Margin vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 EBITDA Margin of 30.3% is the highest of the 11 companies compared; the peer median is -25.7%.
- Its year-over-year change of -11.3 pp is the 8th highest of 11, against a peer median of +4.4 pp.
- Over three fiscal years its change of +119.0 pp compares with a peer median of +70.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 30.3% | -11.3 pp | +119.0 pp | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | 12.6% | +21.8 pp | — |
| LTM Sep 2026 | 6.1% | +10.9 pp | +25.5 pp | |
| LTM Jun 2026 | 1.7% | +5.8 pp | +10.8 pp | |
| LTM Jun 2026 | -6.6% | +4.2 pp | +53.9 pp | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -16.8% | -24.5 pp | +171.2 pp |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -66.6% | +85.7 pp | +198.6 pp | |
| LTM Mar 2026 | -81.4% | -6.3 pp | +87.8 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
| Peer median (excluding ILMN) | -25.7% | +4.4 pp | +70.8 pp | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.53B | 4.58B | 4.5B | 4.37B | 4.34B |
| Cost of Revenue | 1.37B | 1.61B | 1.76B | 1.51B | 1.45B |
| Gross Profit | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| Research & Development | 1.19B | 1.32B | 1.35B | 1.17B | 951M |
| Selling, General & Admin | 2.09B | 1.3B | 1.61B | 1.09B | 1.08B |
| Operating Expenses | 3.28B | 7.15B | 3.81B | 3.69B | 2.03B |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| EBITDA | 1.2B | (3.92B) | (608M) | (725M) | 1.46B |
| EBITDA Margin | 26.4% | -85.4% | -13.5% | -16.6% | 33.6% |
| Operating Income | (123M) | (4.18B) | (1.07B) | (833M) | 864M |
| Operating Margin | -2.7% | -91.2% | -23.7% | -19.1% | 19.9% |
| Interest Income | 0 | 11M | 58M | 46M | 40M |
| Interest Expense | 61M | 26M | 77M | 100M | 101M |
| Other Income / Expenses | 1.01B | (157M) | (48M) | (346M) | 222M |
| Income Before Tax | 884M | (4.34B) | (1.12B) | (1.18B) | 1.09B |
| Pre-Tax Margin | 19.5% | -94.6% | -24.8% | -27.0% | 25.0% |
| Income Tax Expense | 122M | 68M | 44M | 44M | 236M |
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Net Margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (Basic) | 5.08 | (28.05) | (7.35) | (7.69) | 5.48 |
| EPS (Diluted) | 5.05 | (28.05) | (7.35) | (7.69) | 5.45 |
| Weighted Avg Shares | 150M | 157M | 158M | 159M | 155M |
| Weighted Avg Shares (Diluted) | 151M | 157M | 158M | 159M | 156M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.